Risk-based and diagnostics-linked personalized medicine for cancer

Authors: Srivastava, Sudhir; Wagner, Paul D

Source: Personalized Medicine, Volume 4, Number 1, February 2007 , pp. 33-43(11)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Personalized medicine is gaining momentum in healthcare by allowing physicians to determine an individual's predisposition to different diseases and to better diagnose and treat those diseases. Personalized medicine is frequently described as the right drug for the right patient at the right time; that is, a physician will prescribe treatment based on the individual characteristics of each patient such that the patient is likely to respond to a particular treatment with minimal adverse events. The heterogeneity of cancer makes the implementation of personalized medicine a necessity.

Keywords: biomarkers; cancer; oncogenes; raloxifene; risk assessment; tamoxifen; tumor suppressor genes

Document Type: Research article

DOI: http://dx.doi.org/10.2217/17410541.4.1.33

Affiliations: 1: 1Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Boulevard, Suite 3142, Rockville, MD 20892, USA., Email: ss1a@nih.gov

Publication date: 2007-02-01

More about this publication?

Personalized Medicine translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
E-Access Trials
ingentaconnect is not responsible for the content or availability of external websites